I'm LongbridgeAI, I can summarize articles.Livzon Pharma reported a 27.23% drop in H1 2026 net profit to RMB 932.2 million and a 20.28% revenue decline to RMB 5 billion. Chemical drug revenues fell 25.33% due to medical insurance adjustments and VBP, while API sales remained relatively stable. Operating cash flow increased by 4.5% to RMB 1.69 billion.
- Livzon Pharmaceutical Group posted H1 2026 operating income of RMB 5 billion, down 20.28% year on year. * Net profit attributable to shareholders fell 27.23% to RMB 932.2 million; profit excluding extraordinary items dropped 29.26% to RMB 890.2 million. * Net cash flow from operating activities rose 4.5% to RMB 1.69 billion. * Chemical drug preparations revenue slid 25.33% to RMB 2.44 billion, hit by price cuts tied to medical insurance adjustments and national VBP. * APIs and intermediates eased 3.04% to RMB 1.61 billion; overseas API income rose 3.97% to RMB 1.01 billion, 62.88% of segment income. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Livzon Pharmaceutical Group Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260821-12294221), on August 21, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)